Page last updated: 2024-10-15

tetra(4-n-methylpyridyl)porphine

Description

tetra(4-N-methylpyridyl)porphine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135398505
SCHEMBL ID265519
MeSH IDM0075564

Synonyms (27)

Synonym
meso-(n-methylpyridyl)porphine
5,10,15,20-tetra-ris[4-(n-methylpyridino)]21h, 23h-porphine
(5z,10z,14z,19z)-5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,23-dihydroporphyrin
tmpyp
POH ,
(1z,4z,9z,15z)-5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,23-dihydroporphyrin
meso-tetrakis(n-methyl-4-pyridinium)phenyl porphyrin
4,4',4'',4'''-porphyrin-5,10,15,20-tetrayltetrakis(1-methylpyridinium)
38673-65-3
meso-tetrakis(2-n-methylpyridyl)porphine
5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin
tetra(4-n-methylpyridyl)porphine
meso-tetra(4-n-methylpyridyl)porphine
tetrakis(4-n-methylpyridyl)porphine
5,10,15,20-tetrakis(n-methylpyridinium-4-yl)-21h,23h-porphine
(4,4',4'',4'''-(21h,23h)-porphine-5,10,15,20-tetrayl)tetrakis(1-methylpyridinium)
meso-tetrakis(n-methyl-4-pyridyl)porphine
tetrakis(n-methyl-4-pyridino)porphine
mesotetra(4-n-methylpyridyl)porphine
tmpyp4
meso-tetra(4-n-methylpyridyl)porphine tetraperchlorate
5,10,15,20-tetrakis(n-methyl-4-pyridyl)-21h,23h-porphine
SCHEMBL265519
DTXSID301267713
tetrakis(1-methylpyridinium-4-yl)porphyrin
NCGC00387155-01
5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,23-dihydroporphyrin

Toxicity

ExcerptReference
" Toxic effects of TMPyP disappeared after addition of histidine, quenching residual ROS."( A Closer Look at Dark Toxicity of the Photosensitizer TMPyP in Bacteria.
Bäumler, W; Dengler, L; Eckl, DB; Eichner, A; Huber, H; Nemmert, M, 2018
)

Compound-Compound Interactions

ExcerptReference
"This study aimed to determine if Photodynamic Antimicrobial Chemotherapy (PACT) was effective in the treatment of Burkholderia cepacia complex infection and whether a synergistic effect was evident if PACT was used in combination with antibiotics."( Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection.
Cassidy, CM; Donnelly, RF; Elborn, JS; Magee, ND; Tunney, MM, 2012
)

Bioavailability

ExcerptReference
" UVB is well absorbed in proteins and DNA leading to products such as cyclobutane pyrimidine dimers."( Fatty acids and vitamins generate singlet oxygen under UVB irradiation.
Bäumler, W; Knak, A; Landthaler, M; Maisch, T; Regensburger, J, 2012
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (314)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (5.73)18.7374
1990's33 (10.51)18.2507
2000's108 (34.39)29.6817
2010's132 (42.04)24.3611
2020's23 (7.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.61%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other324 (99.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]